COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics reçoit un deuxième avis positif du Comité Indépendant de Surveillance des Données (IDMC) pour l’essai pivot de Phase 3 ARTEMIA évaluant Tedopi® dans le cancer du poumon non à petites cellules
26/02/2026
Nantes, le 26 février 2026 – 18h00 CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) annonce aujourd’hui que le Comité Indépendant de Surveillance des Données (IDMC) a émis une deuxième recommandation [...]
Trading by management and close relations of management
26/02/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
USOSM Commends Surgeon Partner Dr. Wendy Liao on Her Medical Mission Work in The Philippines
26/02/2026
Team Provided Pro Bono Dental care to 1,739 Students IRVING, Texas and ALAMEDA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM ) salutes its surgeon partner Wendy Liao, DDS, as she [...]
BeautyHealth to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
26/02/2026
LONG BEACH, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report fourth quarter and full year 2025 financial results [...]
AMN Healthcare Survey Reveals Sharp Divide Between Leaders’ Organizational Confidence and Industry Outlook for 2026
26/02/2026
Survey of 700+ executives shows AI leadership roles surging as succession planning and clinician engagement lag DALLAS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- While nearly three-quarters of healthcare executives believe [...]
CurePSP Explains Progressive Supranuclear Palsy After Rev. Jesse L. Jackson’s Passing
26/02/2026
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The passing of Rev. Jesse L. Jackson, Sr. has cast a spotlight on progressive supranuclear palsy (PSP), one of the most misunderstood neurodegenerative diseases affecting [...]
Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026
26/02/2026
Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Curium, a world [...]
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
26/02/2026
NANTES, France, February 26, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced that the Independent Data Monitoring Committee (IDMC) has issued a second positive [...]
ImageneBio to Participate in Leerink Global Healthcare Conference
26/02/2026
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink [...]
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
26/02/2026
Recognized expert in cancer biology, RNA biology and translational therapeutics with 20 years of experience in preclinical oncology drug discovery and development TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE [...]
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
26/02/2026
Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced [...]
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
26/02/2026
Physician Interview Now Available Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint [...]
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
26/02/2026
Results from IV Phase 1 SAD/MAD Trial Expected in 2026 JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent [...]
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
26/02/2026
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
26/02/2026
Accepted Abstract Highlights Metabolic Response Observations Following Chemotherapeutic Drug-Delivery via the TAMP™ Therapy Platform in Patients Diagnosed with Locally Advanced Pancreatic Cancer MOUNTAIN VIEW, Calif., [...]
Glow Holdings, Inc. Launches New Corporate Website
26/02/2026
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Glow Holdings, Inc. (OTC: GLOH), doing business as GlohCo, an emerging healthtech company developing AI-powered software and data-driven tools for mental health, behavioral [...]
NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome
26/02/2026
Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions ASHBURN, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day® 2026, Quoin Pharmaceuticals Ltd. ( [...]
GATC Health Strengthens Commercial and Pharma Strategy Leadership to Accelerate Market Adoption of Its AI Platform
26/02/2026
Mark Flather and Dr. Fred Brown join to expand adoption of Derisq™ and Operon™, delivering AI-powered risk prediction and portfolio optimization for biotech investors and pharmaceutical partners. Appointments come as [...]
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
26/02/2026
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that [...]

Pages